These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162 [TBL] [Abstract][Full Text] [Related]
3. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Seferović PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschöpe C; Hoes AW; Seferović JP; Logue J; McDonagh T; Riley JP; Milinković I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964 [TBL] [Abstract][Full Text] [Related]
4. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis. Kramer CK; Ye C; Campbell S; Retnakaran R JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071 [TBL] [Abstract][Full Text] [Related]
5. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
6. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. Asleh R; Sheikh-Ahmad M; Briasoulis A; Kushwaha SS Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818 [TBL] [Abstract][Full Text] [Related]
7. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India. Fatima Z; Atal S; Joshi R; Sadasivam B Cureus; 2022 Feb; 14(2):e22141. PubMed ID: 35308676 [TBL] [Abstract][Full Text] [Related]
8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
9. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. Dawwas GK; Smith SM; Park H Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Thrasher J Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182 [TBL] [Abstract][Full Text] [Related]
11. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity? Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303 [TBL] [Abstract][Full Text] [Related]
12. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774 [TBL] [Abstract][Full Text] [Related]
13. Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. Savarese G; Schrage B; Cosentino F; Lund LH; Rosano GMC; Seferovic P; Butler J ESC Heart Fail; 2020 Dec; 7(6):3438-3451. PubMed ID: 32909376 [TBL] [Abstract][Full Text] [Related]
14. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. Sharma A; Ezekowitz JA Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988 [TBL] [Abstract][Full Text] [Related]
15. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997 [TBL] [Abstract][Full Text] [Related]
16. Adverse effects and safety of SGLT-2 inhibitors. Halimi S; Vergès B Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. Yandrapalli S; Aronow WS J Thorac Dis; 2017 Jul; 9(7):2124-2134. PubMed ID: 28840014 [TBL] [Abstract][Full Text] [Related]
18. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Fitchett DH; Udell JA; Inzucchi SE Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447 [TBL] [Abstract][Full Text] [Related]
19. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914 [No Abstract] [Full Text] [Related]
20. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease. Aftab S; Vetrivel Suresh R; Sherali N; Daniyal M; Tsouklidis N Cureus; 2020 Oct; 12(10):e10783. PubMed ID: 33042651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]